Skoči na glavni sadržaj

Izvorni znanstveni članak

https://doi.org/10.13112/PC.2014.3

Urolithiasis – a potential complication of ceftriaxone therapy

Daniel Turudić ; Medicinski fakultet Sveučilišta u Zagrebu, 10000 Zagreb
Danica Batinić ; Medicinski fakultet Sveučilišta u Zagrebu, Klinički bolnički centar Zagreb, Zavod za nefrologiju, dijalizu i transplantaciju, 10000 Zagreb
Branko Miše ; Zavod za dječje zarazne bolesti, Sveučilište u Zagrebu, 10000 Zagreb
Ivan Habuš ; Odjel za fi zikalnu kemiju Instituta „Ruđer Bošković“, 10000 Zagreb
Marija Spajić ; Opća bolnica Karlovac, Karlovac
Goran Krnjak ; Medicinski fakultet Sveučilišta u Zagrebu, Klinički bolnički centar Zagreb, Zavod za nefrologiju, dijalizu i transplantaciju, 10000 Zagreb
Danko Milošević ; Medicinski fakultet Sveučilišta u Zagrebu, Klinički bolnički centar Zagreb, Zavod za nefrologiju, dijalizu i transplantaciju, 10000 Zagreb



Sažetak

A cohort of 238 children diagnosed with cystopyelonephritis were retrospectively analyzed in 2011 to assess the possible ceftriaxone
risk of urinary stone formation. All children were treated with ceftriaxone in a standard dosage of 60 mg/kg/day for 10 days. Urinary
tract imaging revealed anomalies in 73, vesicoureteral refl ux in 66 and hydronephrosis in 7 children. No ceftriaxone stone formation
and no sign of abdominal colic or macro/microhematuria was found during one-month monitoring. Ceftriaxone administration is
quite safe in the usual dosage of 60 mg/kg/24 h for 10 days. Caution is only warranted in children requiring higher dosage of ≥100
mg/kg/24 h and prolonged administration. In such cases, we recommend ultrasound of urinary tract and gallbladder screening for
hypercalciuria and alkalization of urine.

Ključne riječi

ceftriaxone, urinary calculi, urinary tract infections

Hrčak ID:

119997

URI

https://hrcak.srce.hr/119997

Podaci na drugim jezicima: hrvatski

Posjeta: 812 *